Adam P. Silverman, Ph.D

Company: Codexis

Job title: Senior Director, Therapeutics Discovery

Seminars:

Applications of Directed Evolution Toward Reducing The Immunogenicity Risk of Transgenes 12:00 pm

Transgenes may lead to neutralizing antibodies that impact their safety and efficacy in patients Immunogenicity risk of transgenes can be reduced by increasing protein stability or removing putative T cell epitopes We discuss applications of the CodeEvolver® directed evolution platform toward engineering transgenes with reduced immunogenicity risk profiles for lysosomal storage diseasesRead more

day: Day 2 Tracks 1 AM